UAE Begins Mapping Air Corridors for Air Taxis and Cargo Drones to Transform Urban Transportation
Initial advanced air mobility (AAM) regulations under development for the UAE GCAA and ATRC entities – TII and ASPIRE collaborate on technical expertise and airspace management
The UAE has taken a bold step towards redefining urban transportation with the commencement of air corridor mapping and regulatory framework development for piloted and autonomous air taxis and cargo drones. This transformative initiative marks a major leap forward in the nation’s mission to lead the future of mobility. Through a strategic partnership between the General Civil Aviation Authority (GCAA) and the Advanced Technology Research Council (ATRC) entities—Technology Innovation Institute (TII) and ASPIRE—the UAE is on track to reshape the way people and goods move through urban spaces.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213996930/en/
UAE Begins Mapping Air Corridors for Air Taxis and Cargo Drones to Transform Urban Transportation (Photo: AETOSWire)
With aerial corridors and regulations set to be defined within the next 20 months, this pioneering effort demonstrates the UAE’s unwavering commitment to deploying safe, advanced, sustainable transportation solutions that will not only ease congestion but also set a global benchmark for future urban mobility systems. These routes will connect key international airports and iconic places in the UAE, extending further to ensure seamless integration of piloted and autonomous air taxis and cargo drones across the nation’s urban landscapes.
His Excellency Saif Mohammed Al Suwaidi, Director General of the GCAA said: “Air corridor mapping for piloted and autonomous air taxis and drones is a crucial milestone that will enable the seamless implementation of Advanced Air Mobility into the UAE’s infrastructure. This initiative ensures the safe and efficient adoption of air mobility, delivering transformative solutions to urban transport and paving the way for a smarter, more connected future.”
The UAE’s forward-thinking approach to urban transportation will be supported by TII’s expertise in airspace management, ensuring the safe integration of piloted and autonomous air taxis and cargo drones into urban environments. These new air corridors will offer innovative solutions for passenger and cargo transport, relieving pressure on traditional road networks and improving connectivity.
Dr. Najwa Aaraj, CEO of TII, said: “This transformative collaboration with GCAA is reshaping the future of urban transportation. By advancing airspace management and integrating piloted and autonomous air taxis and cargo drones, we are not only enhancing urban connectivity but also driving sustainable and accessible mobility solutions that will benefit future generations.”
Stephane Timpano from ASPIRE said: “Addressing real-time urban mobility challenges through innovative solutions like air taxis and drones is a major step forward. This initiative directly supports sustainable economic growth by creating a flexible and diverse transport system that eases pressure on urban infrastructure and fosters smarter, more resilient cities.”
The agreement was announced during World Governments Summit 2025.
Advanced Air Mobility (AAM) refers to the use of automated aircraft in urban and suburban settings to deliver innovative transport solutions for people and goods. With TII at the helm of developing the technical aspects of AAM and ASPIRE focusing on creating a network of stakeholders, including regulators, industry leaders, and researchers, this collaboration aims to establish a comprehensive regulatory framework that ensures safety and operational efficiency.
Prof. Enrico Natalizio, Chief Researcher of the Autonomous Robotics Research Center at TII, commented: “At TII, we’re developing advanced AI-powered control, vision and communication algorithms for autonomous systems that enable real-time decision-making for air taxis and drones. Having mastered this technology, we are able to propose methodologies for AAM corridors design to optimize routes, ensure collision avoidance, and integrate seamlessly with urban airspace, marking a key step toward efficient and safe autonomous air mobility in complex urban environments.”
Together with GCAA, these entities will define the airspace regulations and develop airspace management systems, making the UAE a global benchmark for advanced urban mobility.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213996930/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom